Quinazoline-2,4(1 H,3 H)-dione Scaffold for development of a novel PARP-targeting PET probe for tumor imaging.

IF 8.6 1区 医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Chunfeng He, Hui Shi, Boyu Tan, Zhaoning Jiang, Rui Cao, Jiamin Zhu, Kun Qian, Xiao Wang, Xiaoping Xu, Chunrong Qu, Shaoli Song, Zhen Cheng
{"title":"Quinazoline-2,4(1 H,3 H)-dione Scaffold for development of a novel PARP-targeting PET probe for tumor imaging.","authors":"Chunfeng He, Hui Shi, Boyu Tan, Zhaoning Jiang, Rui Cao, Jiamin Zhu, Kun Qian, Xiao Wang, Xiaoping Xu, Chunrong Qu, Shaoli Song, Zhen Cheng","doi":"10.1007/s00259-024-06843-2","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Overexpression of Poly (ADP-ribose) polymerase (PARP) is associated with many diseases such as oncological diseases. Several PARP-targeting radiotracers have been developed to detect tumor in recent years. Two <sup>18</sup>F labelled probes based on Olaparib and Rucaparib molecular scaffolds have been evaluated in clinical trials, but their slow hepatic clearance hinders their tumor imaging performance. Although a number of positron emission tomography (PET) probes with lower liver uptake have been designed, the tumor to background ratios remains to be low. Therefore, we designed a probe with low lipid-water partition coefficient to solve this problem.</p><p><strong>Methods: </strong>A pyridine-containing quinazoline-2,4(1 H,3 H)-dione PARP-targeting group was rationally designed and used to conjugate with the chelator 2,2',2'',2'''-(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetraacetic acid (DOTA) to prepare the lead compound named as SMIC-2001 for radiolabeling. In vitro experiments, the lipid-water partition coefficient, stability, binding affinity, and cellular uptake of [<sup>68</sup>Ga]Ga-SMIC-2001 were determined. In vivo experiments, the U87MG xenograft models were used to evaluate its tumor imaging properties.</p><p><strong>Results: </strong>[<sup>68</sup>Ga]Ga-SMIC-2001 showed a low Log D<sub>7.4</sub> (-3.82 ± 0.06) and high affinity for PARP-1 (48.13 nM). In vivo study revealed that it exhibited a high tumor-to-background contrast in the U87MG xenograft models and mainly renal clearance. And the ratios of tumor to main organs were high except for the kidney (e.g. tumor to liver ratio reached 2.20 ± 0.51) at 60 min p.i.</p><p><strong>Conclusion: </strong>In summary, pyridine-containing quinazoline-2,4(1 H,3 H)-dione is a novel PARP-targeting molecular scaffold for imaging probe development, and [<sup>68</sup>Ga]Ga-SMIC-2001 is a highly promising PET probe capable of imaging tumors with PARP overexpression.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":null,"pages":null},"PeriodicalIF":8.6000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Nuclear Medicine and Molecular Imaging","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00259-024-06843-2","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/16 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: Overexpression of Poly (ADP-ribose) polymerase (PARP) is associated with many diseases such as oncological diseases. Several PARP-targeting radiotracers have been developed to detect tumor in recent years. Two 18F labelled probes based on Olaparib and Rucaparib molecular scaffolds have been evaluated in clinical trials, but their slow hepatic clearance hinders their tumor imaging performance. Although a number of positron emission tomography (PET) probes with lower liver uptake have been designed, the tumor to background ratios remains to be low. Therefore, we designed a probe with low lipid-water partition coefficient to solve this problem.

Methods: A pyridine-containing quinazoline-2,4(1 H,3 H)-dione PARP-targeting group was rationally designed and used to conjugate with the chelator 2,2',2'',2'''-(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetraacetic acid (DOTA) to prepare the lead compound named as SMIC-2001 for radiolabeling. In vitro experiments, the lipid-water partition coefficient, stability, binding affinity, and cellular uptake of [68Ga]Ga-SMIC-2001 were determined. In vivo experiments, the U87MG xenograft models were used to evaluate its tumor imaging properties.

Results: [68Ga]Ga-SMIC-2001 showed a low Log D7.4 (-3.82 ± 0.06) and high affinity for PARP-1 (48.13 nM). In vivo study revealed that it exhibited a high tumor-to-background contrast in the U87MG xenograft models and mainly renal clearance. And the ratios of tumor to main organs were high except for the kidney (e.g. tumor to liver ratio reached 2.20 ± 0.51) at 60 min p.i.

Conclusion: In summary, pyridine-containing quinazoline-2,4(1 H,3 H)-dione is a novel PARP-targeting molecular scaffold for imaging probe development, and [68Ga]Ga-SMIC-2001 is a highly promising PET probe capable of imaging tumors with PARP overexpression.

Abstract Image

用于开发新型 PARP 靶向 PET 探针的喹唑啉-2,4(1H,3H)-二酮支架,用于肿瘤成像。
目的:多聚(ADP-核糖)聚合酶(PARP)的过度表达与肿瘤等多种疾病有关。近年来,已开发出多种用于检测肿瘤的 PARP 靶向放射性探针。基于奥拉帕利(Olaparib)和鲁卡帕利(Rucaparib)分子支架的两种 18F 标记探针已在临床试验中进行了评估,但其缓慢的肝清除率阻碍了其肿瘤成像性能。虽然已设计出一些肝摄取率较低的正电子发射断层扫描(PET)探针,但肿瘤与背景的比率仍然很低。因此,我们设计了一种脂水分配系数较低的探针来解决这一问题:方法:我们合理设计了一种含吡啶的喹唑啉-2,4(1 H,3 H)-二酮 PARP 靶向基团,并将其与螯合剂 2,2',2'',2'''-(1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸)(DOTA)共轭,制备了用于放射性标记的先导化合物 SMIC-2001。体外实验测定了[68Ga]Ga-SMIC-2001的脂水分配系数、稳定性、结合亲和力和细胞摄取率。在体内实验中,使用 U87MG 异种移植模型评估其肿瘤成像特性:结果:[68Ga]Ga-SMIC-2001显示出较低的Log D7.4(-3.82 ± 0.06)和对PARP-1的高亲和力(48.13 nM)。体内研究显示,它在 U87MG 异种移植模型中表现出较高的肿瘤与背景对比度,主要通过肾脏清除。在 60 分钟p.i.时,除肾脏外,肿瘤与主要器官的比值较高(如肿瘤与肝脏的比值达到 2.20 ± 0.51):综上所述,含吡啶的喹唑啉-2,4(1 H,3 H)-二酮是一种新型的PARP靶向分子支架,可用于成像探针的开发,而[68Ga]Ga-SMIC-2001是一种非常有前景的PET探针,能够对PARP过度表达的肿瘤进行成像。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
15.60
自引率
9.90%
发文量
392
审稿时长
3 months
期刊介绍: The European Journal of Nuclear Medicine and Molecular Imaging serves as a platform for the exchange of clinical and scientific information within nuclear medicine and related professions. It welcomes international submissions from professionals involved in the functional, metabolic, and molecular investigation of diseases. The journal's coverage spans physics, dosimetry, radiation biology, radiochemistry, and pharmacy, providing high-quality peer review by experts in the field. Known for highly cited and downloaded articles, it ensures global visibility for research work and is part of the EJNMMI journal family.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信